{"hands_on_practices": [{"introduction": "A core competency in clinical psychopharmacology is the ability to adjust dosing regimens to account for drug-drug interactions. This first exercise provides a foundational practice in this skill, focusing on a common scenario where a metabolic inhibitor is introduced. By working through this problem [@problem_id:4708607], you will apply the principle of mass balance at steady state to calculate a necessary dose adjustment, reinforcing the direct, proportional relationship between clearance ($CL$) and the required dose to maintain a target drug concentration.", "problem": "A patient stabilized on an oral psychotropic with linear, time-invariant pharmacokinetics is receiving a maintenance regimen that has achieved steady state. The average steady-state plasma concentration (average steady-state concentration, $C_{ss,avg}$) is defined as the time-average over one dosing interval at steady state. For drugs exhibiting linear pharmacokinetics at steady state, mass balance implies that the average rate of systemic input over one dosing interval equals the average rate of elimination, and that the average rate of elimination equals the product of clearance (clearance, $CL$) and $C_{ss,avg}$. The systemic input rate depends on oral bioavailability (oral bioavailability, $F$), the administered dose (dose, $Dose$), and the dosing interval (dosing interval, $\\tau$). Assume instantaneous absorption relative to the dosing interval, no autoinduction or time-dependent clearance, and adherence is perfect.\n\nBaseline regimen and parameters:\n- $F = 0.80$\n- $Dose = 100$ mg every $\\tau = 12$ h\n- $CL = 25$ L/h\n\nA strong cytochrome P450 inhibitor is introduced that reduces $CL$ by 40%. The inhibitor does not alter $F$, protein binding, the volume of distribution, or $\\tau$, and the pharmacokinetics remain linear.\n\nTasks:\n1. Using first principles described above, determine the new $C_{ss,avg}$ if the $Dose$ and $\\tau$ are left unchanged after the inhibitor is added.\n2. Then, determine the single per-dose amount $Dose_{new}$ that would restore the original baseline $C_{ss,avg}$ under the inhibited $CL$ while keeping $F$ and $\\tau$ unchanged.\n\nRound the final reported answer to three significant figures. Express the final reported answer as the adjusted dose in mg. Report only the adjusted dose as your final answer.", "solution": "The problem is evaluated as valid, as it is scientifically grounded in the principles of pharmacokinetics, internally consistent, and possesses all necessary information for a unique solution.\n\nThe fundamental principle provided is the mass balance at steady state, where the average rate of systemic drug input equals the average rate of drug elimination. The average rate of systemic input is the fraction of the dose that reaches systemic circulation, which is the product of bioavailability ($F$) and the dose ($Dose$), averaged over the dosing interval ($\\tau$). The average rate of elimination is given as the product of the total body clearance ($CL$) and the average steady-state plasma concentration ($C_{ss,avg}$).\n\nThis relationship can be expressed mathematically as:\n$$\n\\text{Rate of Input} = \\text{Rate of Elimination}\n$$\n$$\n\\frac{F \\cdot Dose}{\\tau} = CL \\cdot C_{ss,avg}\n$$\nFrom this equation, the average steady-state concentration can be expressed as:\n$$\nC_{ss,avg} = \\frac{F \\cdot Dose}{CL \\cdot \\tau}\n$$\nLet the baseline parameters be denoted without a subscript and the new parameters after adding the inhibitor be denoted with the subscript '$new$'. The baseline steady-state concentration is:\n$$\nC_{ss,avg} = \\frac{F \\cdot Dose}{CL \\cdot \\tau}\n$$\nThe problem states that a new drug, a cytochrome P450 inhibitor, is introduced. This inhibitor reduces the clearance ($CL$) by 40%. Let the original clearance be $CL_{original}$ and the new clearance be $CL_{new}$. The new clearance is 60% of the original:\n$$\nCL_{new} = CL_{original} \\cdot (1 - 0.40) = 0.60 \\cdot CL_{original}\n$$\nThe first task is to determine the new steady-state concentration, $C_{ss,avg,new}$, if the dose and dosing interval are unchanged. However, the second task, which provides the required final answer, is to find the adjusted dose ($Dose_{new}$) that would restore the original baseline $C_{ss,avg}$ under the inhibited clearance conditions.\n\nThe goal is to achieve the same steady-state concentration as the baseline regimen, but with the new clearance. Therefore, we must set the target concentration with the new regimen equal to the baseline concentration:\n$$\nC_{ss,avg,new} = C_{ss,avg,original}\n$$\nUsing the governing equation for each condition:\n$$\n\\frac{F_{new} \\cdot Dose_{new}}{CL_{new} \\cdot \\tau_{new}} = \\frac{F_{original} \\cdot Dose_{original}}{CL_{original} \\cdot \\tau_{original}}\n$$\nThe problem states that the inhibitor does not alter bioavailability ($F$) or the dosing interval ($\\tau$). Thus, $F_{new} = F_{original}$ and $\\tau_{new} = \\tau_{original}$. These terms can be canceled from both sides of the equation:\n$$\n\\frac{Dose_{new}}{CL_{new}} = \\frac{Dose_{original}}{CL_{original}}\n$$\nWe can solve for the new dose, $Dose_{new}$:\n$$\nDose_{new} = Dose_{original} \\cdot \\frac{CL_{new}}{CL_{original}}\n$$\nThis relationship shows that to maintain the same average steady-state concentration, the dose must be adjusted in direct proportion to the clearance.\n\nWe are given the following baseline and new parameters:\n- Baseline Dose, $Dose_{original} = 100$ mg\n- Baseline Clearance, $CL_{original} = 25$ L/h\n- New Clearance, $CL_{new} = 0.60 \\cdot CL_{original} = 0.60 \\cdot 25 \\text{ L/h} = 15$ L/h\n\nSubstituting these values into the expression for $Dose_{new}$:\n$$\nDose_{new} = 100 \\text{ mg} \\cdot \\frac{15 \\text{ L/h}}{25 \\text{ L/h}}\n$$\n$$\nDose_{new} = 100 \\text{ mg} \\cdot 0.60\n$$\n$$\nDose_{new} = 60 \\text{ mg}\n$$\nThe problem requires the final answer to be rounded to three significant figures. The calculated value is $60$ mg. To express this with three significant figures, we write it as $60.0$ mg.", "answer": "$$\\boxed{60.0}$$", "id": "4708607"}, {"introduction": "Clinical reality is often more complex than a single metabolic pathway. This practice problem [@problem_id:4708625] advances our model by considering a drug that is a dual substrate for two different enzymes, a common occurrence. You will learn to use the concept of fractional metabolism ($f_m$) to partition the drug's total clearance and predict the net change in exposure when only one of these parallel pathways is affected by an inducer, a crucial skill for assessing interactions with poly-metabolized drugs.", "problem": "A psychiatric patient enrolled in a pharmacokinetic study receives an intravenous dose of a psychotropic drug that is a dual substrate of Cytochrome P450 3A4 (CYP3A4) and Cytochrome P450 2D6 (CYP2D6). The study uses single-dose intravenous administration specifically to isolate systemic clearance. At baseline, the total systemic clearance is the sum of pathway-specific clearances. The drug’s fractional metabolic contributions are measured as follows: the fraction metabolized by CYP3A4 is $f_{m,3\\mathrm{A}4} = 0.45$, the fraction metabolized by CYP2D6 is $f_{m,2\\mathrm{D}6} = 0.35$, and the remaining fraction $f_{\\text{other}} = 0.20$ is via other pathways unaffected by the perpetrator drug. A strong inducer is then introduced that selectively affects CYP3A4, increasing the intrinsic clearance contribution of CYP3A4 by a fold-induction factor $\\rho = 2.5$, while leaving CYP2D6 and other pathways unchanged. Assume linear pharmacokinetics, constant bioavailability due to intravenous dosing, and that the area under the plasma concentration–time curve (AUC) is inversely proportional to total systemic clearance for a given dose. Using $f_m$ partitioning that treats total clearance as the sum of independent pathway clearances, determine the predicted net exposure change, reported as the dimensionless ratio $AUC_{\\text{induced}}/AUC_{\\text{baseline}}$. Round your final answer to four significant figures.", "solution": "The problem requires the calculation of the predicted change in drug exposure, quantified by the ratio of the area under the plasma concentration-time curve (AUC) after enzyme induction to the baseline AUC. The solution will be derived from first principles of pharmacokinetics.\n\nFirst, the givens from the problem statement are meticulously extracted and validated.\n- Fractional metabolic contribution of CYP3A4: $f_{m,3\\mathrm{A}4} = 0.45$.\n- Fractional metabolic contribution of CYP2D6: $f_{m,2\\mathrm{D}6} = 0.35$.\n- Fractional metabolic contribution of other pathways: $f_{\\text{other}} = 0.20$.\n- The sum of these fractions is $0.45 + 0.35 + 0.20 = 1.00$, which is consistent.\n- A selective inducer of CYP3A4 increases its intrinsic clearance by a fold-induction factor $\\rho = 2.5$.\n- Administration is intravenous, implying bioavailability $F=1$.\n- A key assumption is that AUC for a given dose is inversely proportional to total systemic clearance ($CL_{\\text{total}}$).\n- The problem is chemically and biologically grounded in the principles of drug metabolism and pharmacokinetics, well-posed, and objective. It is therefore deemed valid.\n\nThe total systemic clearance, $CL_{\\text{total}}$, is the sum of the clearances via all parallel elimination pathways. At baseline, we can write:\n$$CL_{\\text{total, baseline}} = CL_{3\\mathrm{A}4} + CL_{2\\mathrm{D}6} + CL_{\\text{other}}$$\nThe fractional metabolism for a specific enzyme pathway, $f_m$, is defined as the ratio of the clearance via that pathway to the total systemic clearance.\n$$f_{m,i} = \\frac{CL_{i}}{CL_{\\text{total}}}$$\nTherefore, we can express the baseline pathway-specific clearances in terms of the total baseline clearance:\n$$CL_{3\\mathrm{A}4} = f_{m,3\\mathrm{A}4} \\cdot CL_{\\text{total, baseline}} = 0.45 \\cdot CL_{\\text{total, baseline}}$$\n$$CL_{2\\mathrm{D}6} = f_{m,2\\mathrm{D}6} \\cdot CL_{\\text{total, baseline}} = 0.35 \\cdot CL_{\\text{total, baseline}}$$\n$$CL_{\\text{other}} = f_{\\text{other}} \\cdot CL_{\\text{total, baseline}} = 0.20 \\cdot CL_{\\text{total, baseline}}$$\n\nUpon introduction of the inducer, the clearance via the CYP3A4 pathway is increased by the fold-induction factor $\\rho$. The new clearance for this pathway, $CL'_{3\\mathrm{A}4}$, is:\n$$CL'_{3\\mathrm{A}4} = \\rho \\cdot CL_{3\\mathrm{A}4} = 2.5 \\cdot (0.45 \\cdot CL_{\\text{total, baseline}})$$\nThe problem states that the other pathways are unaffected, so their clearances remain unchanged:\n$$CL'_{2\\mathrm{D}6} = CL_{2\\mathrm{D}6} = 0.35 \\cdot CL_{\\text{total, baseline}}$$\n$$CL'_{\\text{other}} = CL_{\\text{other}} = 0.20 \\cdot CL_{\\text{total, baseline}}$$\n\nThe new total systemic clearance in the induced state, $CL_{\\text{total, induced}}$, is the sum of these modified pathway clearances:\n$$CL_{\\text{total, induced}} = CL'_{3\\mathrm{A}4} + CL'_{2\\mathrm{D}6} + CL'_{\\text{other}}$$\nSubstituting the expressions in terms of $CL_{\\text{total, baseline}}$:\n$$CL_{\\text{total, induced}} = (2.5 \\cdot 0.45 \\cdot CL_{\\text{total, baseline}}) + (0.35 \\cdot CL_{\\text{total, baseline}}) + (0.20 \\cdot CL_{\\text{total, baseline}})$$\nWe can factor out $CL_{\\text{total, baseline}}$:\n$$CL_{\\text{total, induced}} = (2.5 \\cdot 0.45 + 0.35 + 0.20) \\cdot CL_{\\text{total, baseline}}$$\nLet's compute the value of the term in parentheses:\n$$2.5 \\cdot 0.45 + 0.35 + 0.20 = 1.125 + 0.35 + 0.20 = 1.675$$\nSo, the relationship between the induced total clearance and the baseline total clearance is:\n$$CL_{\\text{total, induced}} = 1.675 \\cdot CL_{\\text{total, baseline}}$$\n\nThe problem requires the ratio of AUC in the induced state to the AUC at baseline, $AUC_{\\text{induced}}/AUC_{\\text{baseline}}$. For intravenous administration, the AUC is given by:\n$$AUC = \\frac{\\text{Dose}}{CL_{\\text{total}}}$$\nSince the dose is constant between the two states, the AUC is inversely proportional to the total systemic clearance. The ratio is therefore:\n$$\\frac{AUC_{\\text{induced}}}{AUC_{\\text{baseline}}} = \\frac{\\frac{\\text{Dose}}{CL_{\\text{total, induced}}}}{\\frac{\\text{Dose}}{CL_{\\text{total, baseline}}}} = \\frac{CL_{\\text{total, baseline}}}{CL_{\\text{total, induced}}}$$\nSubstituting the expression for $CL_{\\text{total, induced}}$:\n$$\\frac{AUC_{\\text{induced}}}{AUC_{\\text{baseline}}} = \\frac{CL_{\\text{total, baseline}}}{1.675 \\cdot CL_{\\text{total, baseline}}} = \\frac{1}{1.675}$$\n\nAs a more general formulation, the ratio can be expressed symbolically. The clearance in the induced state is:\n$$CL_{\\text{total, induced}} = (\\rho \\cdot f_{m,3\\mathrm{A}4} + f_{m,2\\mathrm{D}6} + f_{\\text{other}}) \\cdot CL_{\\text{total, baseline}}$$\nSince $f_{m,3\\mathrm{A}4} + f_{m,2\\mathrm{D}6} + f_{\\text{other}} = 1$, we can write $f_{m,2\\mathrm{D}6} + f_{\\text{other}} = 1 - f_{m,3\\mathrm{A}4}$. Substituting this gives:\n$$CL_{\\text{total, induced}} = (\\rho \\cdot f_{m,3\\mathrm{A}4} + 1 - f_{m,3\\mathrm{A}4}) \\cdot CL_{\\text{total, baseline}} = (1 + (\\rho-1)f_{m,3\\mathrm{A}4}) \\cdot CL_{\\text{total, baseline}}$$\nThe AUC ratio is then:\n$$\\frac{AUC_{\\text{induced}}}{AUC_{\\text{baseline}}} = \\frac{1}{1 + (\\rho-1)f_{m,3\\mathrm{A}4}}$$\nUsing the given values $\\rho = 2.5$ and $f_{m,3\\mathrm{A}4} = 0.45$:\n$$\\frac{AUC_{\\text{induced}}}{AUC_{\\text{baseline}}} = \\frac{1}{1 + (2.5-1) \\cdot 0.45} = \\frac{1}{1 + 1.5 \\cdot 0.45} = \\frac{1}{1 + 0.675} = \\frac{1}{1.675}$$\nFinally, we calculate the numerical value and round it to four significant figures as requested:\n$$\\frac{1}{1.675} \\approx 0.597014925...$$\nRounding to four significant figures yields $0.5970$. This ratio being less than $1$ indicates that the drug exposure is decreased due to the induction of its primary metabolic pathway, which is the expected outcome.", "answer": "$$\\boxed{0.5970}$$", "id": "4708625"}, {"introduction": "This final exercise synthesizes the principles of the preceding problems into a complex and highly realistic clinical scenario involving the antipsychotic clozapine. This problem [@problem_id:4708677] challenges you to simultaneously model the effects of discontinuing an enzyme inducer (smoking cessation) and initiating a potent enzyme inhibitor (fluvoxamine). Mastering this type of integrated analysis demonstrates a sophisticated ability to quantitatively predict the net impact of multiple interacting factors, which is the hallmark of expert practice in psychopharmacology.", "problem": "A patient stabilized on a constant oral dose of clozapine is a daily smoker and has no coadministered cytochrome P450 (CYP) modulators. At time zero, the patient stops smoking and initiates fluvoxamine. Assume linear, time-invariant pharmacokinetics with first-order elimination, unchanged bioavailability and protein binding, and that total clearance is the sum of pathway-specific clearances. The following are known and should be treated as well-tested starting points:\n\n- Clozapine’s hepatic metabolism is dominated by cytochrome P450 family 1 subfamily A member 2 (CYP1A2), with the baseline fraction of total clearance mediated by CYP1A2 equal to $f_m = 0.70$ under a reference state of no induction and no inhibition.\n- In smokers, CYP1A2 catalytic activity is increased by polycyclic aromatic hydrocarbons in tobacco smoke; model this as a multiplicative activity factor $F_{\\text{smoke}} = 1.60$ applied only to the CYP1A2 contribution to clearance.\n- Fluvoxamine is a reversible, competitive inhibitor of CYP1A2. In the patient’s hepatic inlet, the unbound inhibitor concentration to inhibition constant ratio is $I_u/K_i = 9.0$, producing an activity scaling factor for CYP1A2 equal to $1/(1 + I_u/K_i)$, applied only to the CYP1A2 contribution to clearance.\n- Non-CYP1A2 pathways are unaffected by smoking or fluvoxamine and remain at their reference activity.\n\nUsing these premises, derive from first principles an expression for the ratio of the new steady-state area under the concentration–time curve (AUC) after smoking cessation and fluvoxamine initiation to the baseline AUC during smoking without fluvoxamine, and then compute its numerical value. Express the final result as a unitless fold-change (new AUC divided by baseline AUC). Round your answer to $4$ significant figures.", "solution": "The problem statement is evaluated for validity prior to attempting a solution.\n\n### Step 1: Extract Givens\n- A patient is on a constant oral dose of clozapine and is a daily smoker.\n- At time $t=0$, the patient stops smoking and starts fluvoxamine.\n- Assumptions: Linear, time-invariant pharmacokinetics; first-order elimination; unchanged bioavailability and protein binding; total clearance is the sum of pathway-specific clearances.\n- Clozapine metabolism is primarily via CYP1A2.\n- The fraction of total clearance mediated by CYP1A2 in a reference state (no induction/inhibition) is $f_m = 0.70$.\n- Smoking induces CYP1A2 activity with a multiplicative factor $F_{\\text{smoke}} = 1.60$.\n- Fluvoxamine inhibits CYP1A2 with an activity scaling factor of $1/(1 + I_u/K_i)$, where the ratio of unbound inhibitor concentration to inhibition constant is $I_u/K_i = 9.0$.\n- Non-CYP1A2 clearance pathways are unaffected by smoking or fluvoxamine.\n- The task is to derive an expression for the ratio of the new steady-state AUC ($AUC_{\\text{new}}$) to the baseline steady-state AUC ($AUC_{\\text{baseline}}$), and then compute its value rounded to $4$ significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is based on established principles of clinical pharmacokinetics, specifically the mechanisms of enzyme induction and competitive inhibition affecting drug metabolism via cytochrome P450 enzymes. The interaction between clozapine (a CYP1A2 substrate), tobacco smoke (a CYP1A2 inducer), and fluvoxamine (a potent CYP1A2 inhibitor) is a classic, well-documented example in psychopharmacology. The mathematical models used (additive clearances, multiplicative factors for induction, and the Michaelis-Menten-derived term for competitive inhibition) are standard in the field.\n- **Well-Posed**: The problem is well-defined. It provides all necessary parameters to calculate the relative change in total clearance, which in turn determines the change in the area under the concentration-time curve (AUC). The question asks for a ratio, which makes the problem solvable without knowing the absolute dose or baseline clearance. A unique, stable, and meaningful solution exists.\n- **Objective**: The problem is stated using precise, quantitative, and objective language. There are no subjective or opinion-based assertions.\n\n### Step 3: Verdict and Action\nThe problem is valid. It is scientifically sound, well-posed, objective, and internally consistent. A rigorous solution can be derived from the provided information.\n\n### Solution Derivation\nThe steady-state area under the concentration-time curve ($AUC_{ss}$) for a drug administered orally at a constant dosing rate is given by the equation:\n$$ AUC_{ss} = \\frac{F \\cdot \\text{Dose}}{CL_{\\text{tot}}} $$\nwhere $F$ is the bioavailability, `Dose` is the administered dose over a given interval, and $CL_{\\text{tot}}$ is the total systemic clearance of the drug.\n\nThe problem asks for the ratio of the new steady-state AUC ($AUC_{\\text{new}}$) to the baseline steady-state AUC ($AUC_{\\text{baseline}}$).\n$$ \\frac{AUC_{\\text{new}}}{AUC_{\\text{baseline}}} = \\frac{\\frac{F_{\\text{new}} \\cdot \\text{Dose}_{\\text{new}}}{CL_{\\text{tot, new}}}}{\\frac{F_{\\text{baseline}} \\cdot \\text{Dose}_{\\text{baseline}}}{CL_{\\text{tot, baseline}}}} $$\nThe problem states the patient is on a \"constant oral dose,\" so $\\text{Dose}_{\\text{new}} = \\text{Dose}_{\\text{baseline}}$. Bioavailability $F$ is also stated to be unchanged, so $F_{\\text{new}} = F_{\\text{baseline}}$. The expression simplifies to the inverse ratio of the total clearances:\n$$ \\frac{AUC_{\\text{new}}}{AUC_{\\text{baseline}}} = \\frac{CL_{\\text{tot, baseline}}}{CL_{\\text{tot, new}}} $$\nOur task is to determine the total clearance in the baseline and new states.\n\nTotal clearance ($CL_{\\text{tot}}$) is the sum of the clearance mediated by the CYP1A2 pathway ($CL_{\\text{CYP1A2}}$) and the clearance mediated by all other, non-CYP1A2 pathways ($CL_{\\text{non-CYP1A2}}$).\n$$ CL_{\\text{tot}} = CL_{\\text{CYP1A2}} + CL_{\\text{non-CYP1A2}} $$\nLet $CL_{\\text{tot, ref}}$ be the total clearance in a reference state, defined as having no induction from smoking and no inhibition from fluvoxamine. We are given that in this state, the fraction of metabolism via CYP1A2 is $f_m = 0.70$.\nTherefore, we can express the reference pathway clearances as:\n$$ CL_{\\text{CYP1A2, ref}} = f_m \\cdot CL_{\\text{tot, ref}} = 0.70 \\cdot CL_{\\text{tot, ref}} $$\n$$ CL_{\\text{non-CYP1A2}} = (1 - f_m) \\cdot CL_{\\text{tot, ref}} = (1 - 0.70) \\cdot CL_{\\text{tot, ref}} = 0.30 \\cdot CL_{\\text{tot, ref}} $$\nThe problem states that $CL_{\\text{non-CYP1A2}}$ is unaffected by smoking or fluvoxamine, so this component of clearance is constant across all conditions.\n\nNow, we model the total clearance for the two states of interest.\n\n1.  **Baseline State**: Patient is smoking, no fluvoxamine.\n    Smoking induces CYP1A2 activity by a multiplicative factor $F_{\\text{smoke}} = 1.60$. The CYP1A2 clearance is thus increased from its reference value.\n    $$ CL_{\\text{CYP1A2, baseline}} = CL_{\\text{CYP1A2, ref}} \\cdot F_{\\text{smoke}} = (f_m \\cdot CL_{\\text{tot, ref}}) \\cdot F_{\\text{smoke}} $$\n    The total clearance in the baseline state is the sum of the induced CYP1A2 clearance and the unchanged non-CYP1A2 clearance.\n    $$ CL_{\\text{tot, baseline}} = CL_{\\text{CYP1A2, baseline}} + CL_{\\text{non-CYP1A2}} $$\n    $$ CL_{\\text{tot, baseline}} = (f_m \\cdot F_{\\text{smoke}} \\cdot CL_{\\text{tot, ref}}) + ((1 - f_m) \\cdot CL_{\\text{tot, ref}}) $$\n    $$ CL_{\\text{tot, baseline}} = [f_m \\cdot F_{\\text{smoke}} + (1 - f_m)] \\cdot CL_{\\text{tot, ref}} $$\n\n2.  **New State**: Patient stops smoking and initiates fluvoxamine.\n    Stopping smoking removes the induction effect, so CYP1A2 activity reverts to its reference level before considering inhibition. Fluvoxamine inhibits CYP1A2. The activity is scaled by a factor $S_{\\text{inhib}} = \\frac{1}{1 + I_u/K_i}$.\n    Given $I_u/K_i = 9.0$, the inhibition scaling factor is:\n    $$ S_{\\text{inhib}} = \\frac{1}{1 + 9.0} = \\frac{1}{10} = 0.10 $$\n    The CYP1A2 clearance in the new state is its reference value scaled by this inhibition factor.\n    $$ CL_{\\text{CYP1A2, new}} = CL_{\\text{CYP1A2, ref}} \\cdot S_{\\text{inhib}} = (f_m \\cdot CL_{\\text{tot, ref}}) \\cdot S_{\\text{inhib}} $$\n    The total clearance in the new state is:\n    $$ CL_{\\text{tot, new}} = CL_{\\text{CYP1A2, new}} + CL_{\\text{non-CYP1A2}} $$\n    $$ CL_{\\text{tot, new}} = (f_m \\cdot S_{\\text{inhib}} \\cdot CL_{\\text{tot, ref}}) + ((1 - f_m) \\cdot CL_{\\text{tot, ref}}) $$\n    $$ CL_{\\text{tot, new}} = [f_m \\cdot S_{\\text{inhib}} + (1 - f_m)] \\cdot CL_{\\text{tot, ref}} $$\n\nFinally, we compute the ratio of the AUCs using the expressions for total clearance.\n$$ \\frac{AUC_{\\text{new}}}{AUC_{\\text{baseline}}} = \\frac{CL_{\\text{tot, baseline}}}{CL_{\\text{tot, new}}} = \\frac{[f_m \\cdot F_{\\text{smoke}} + (1 - f_m)] \\cdot CL_{\\text{tot, ref}}}{[f_m \\cdot S_{\\text{inhib}} + (1 - f_m)] \\cdot CL_{\\text{tot, ref}}} $$\nThe unknown term $CL_{\\text{tot, ref}}$ cancels, yielding a fully determined expression:\n$$ \\frac{AUC_{\\text{new}}}{AUC_{\\text{baseline}}} = \\frac{f_m \\cdot F_{\\text{smoke}} + (1 - f_m)}{f_m \\cdot S_{\\text{inhib}} + (1 - f_m)} $$\n\nNow, substitute the given numerical values:\n- $f_m = 0.70$\n- $F_{\\text{smoke}} = 1.60$\n- $S_{\\text{inhib}} = 0.10$\n\n$$ \\frac{AUC_{\\text{new}}}{AUC_{\\text{baseline}}} = \\frac{(0.70 \\cdot 1.60) + (1 - 0.70)}{(0.70 \\cdot 0.10) + (1 - 0.70)} $$\n$$ \\frac{AUC_{\\text{new}}}{AUC_{\\text{baseline}}} = \\frac{1.12 + 0.30}{0.07 + 0.30} $$\n$$ \\frac{AUC_{\\text{new}}}{AUC_{\\text{baseline}}} = \\frac{1.42}{0.37} $$\n$$ \\frac{AUC_{\\text{new}}}{AUC_{\\text{baseline}}} \\approx 3.8378378... $$\nRounding the result to $4$ significant figures gives $3.838$. This represents an approximately $3.8$-fold increase in the patient's systemic exposure to clozapine, a clinically significant change.", "answer": "$$\\boxed{3.838}$$", "id": "4708677"}]}